Promotion to full Professor recognizes Dr. Sengupta’s longstanding contributions to biomedical research and translational medicine
Scientific leadership and expertise in drug discovery, bioengineering and
Allowed claims strengthen intellectual property protection around VT-1908 formulations and methods for treating ocular inflammatory diseases
VT-1908 has demonstrated steroid-comparable efficacy in a preclinical
Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governanceVyome Holdings, Inc. (NASDAQ:HIND)
Vyome Holdings, Inc. (NASDAQ:HIND, "Vyome")), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended
Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing
Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1
VT-1953 regulatory
Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market¹
These next-generation JAK inhibitors are
VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015).
70%
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research
Vyome Holdings, Inc. ("Vyome")
Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt
Delivered positive final Phase 2 results for VT-1953 in treating symptoms of
Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026
Livechain, Inc. ("Livechain") (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), announced today that it has
VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety
Plans to generate human clinical data using the India innovation corridor in a very
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M
Independent third-party assessment estimates a current VT-1953
Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product
Vyome Holdings, Inc. ("Vyome" or the "Company") (NASDAQ:HIND) announced it has
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion
Modeled peak annual U.S. sales approaching USD 600 million for VT-1953
Independent valuation analysis estimates
